Q&A: Option Care's John Rademacher

When the ink dries on the planned merger of two of the country's leading home infusion services providers, it will form an organization that is deeply committed to patient care, says John Rademacher, CEO of the combined company of Option Care and BioScrip.

“At the center of both organizations is deep clinical expertise and a passion to deliver extraordinary care,” he told HME News in an email. “Together, we will form an organization that will create a rich environment and a destination for health care and patient service professionals who want to make a meaningful positive difference in their communities.” 

Rademacher answered a few questions questions about why this deal is an exciting opportunity.

HME News: What attracted Option Care to BioScrip?

John Rademacher: BioScrip's long-standing track record of outstanding patient outcomes and service in the communities it serves combined with Option Care's industrial-strength infrastructure, industry-leading quality management system and deep partnerships with health systems and referral sources will create a leading home and alternate site infusion therapy provider in a large and growing segment of the U.S. healthcare industry.

HME: Why was this a good deal for Option Care?

Rademacher: This transaction gives the combined company the capability to serve more patients with cost-effective care throughout the U.S. Our ability to grow should be enhanced by the fact that the combined company will continue to be an independent provider, not tied into any single payer. We also see a tremendous opportunity to bring together two very strong clinical and operating teams that will create an incredible platform to bring innovative solutions to our healthcare partners and patients.” 

HME: Does BioScrip offer any therapies that Option Care wasn't or vice versa?

Rademacher: BioScrip and Option Care both offer top therapeutic solutions and possess complementary portfolios, which will provide a more diversified portfolio by offering products to the combined company that are currently only available to one of the two businesses. For example, Option Care brings to the combined company its access to Cuvitru for the treatment of primary immunodeficiency and to Nuzyra for the treatment of adults with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.